Valganciclovir Description

Valganciclovir is an antiviral medication used to amusement cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is in fact a prodrug for ganciclovir. After articulate administration, it is rapidly adapted to ganciclovir by abdominal and hepatic esterases. After this, it (being an alternation of guanosine) gets congenital into DNA and appropriately cannot be appropriately apprehend by DNA polymerase. This after-effects in the abortion of the addendum of viral DNA.

Valganciclovir is a prodrug of ganciclovir that exists as a admixture of two diastereomers. After administration, these diastereomers are rapidly adapted to ganciclovir by hepatic and abdominal esterases. In cytomegalovirus (CMV)-infected cells, ganciclovir is initially phosphorylated to the monophosphate anatomy by viral protein kinase, again it is added phosphorylated via cellular kinases to aftermath the triphosphate form. This triphosphate anatomy is boring metabolized intracellularly. The phosphorylation is abased aloft the viral kinase and occurs preferentially in virus-infected cells. The virustatic action of ganciclovir is due to the inhibition of viral DNA amalgam by ganciclovir triphosphate. Ganciclovir triphosphate is congenital into the DNA fiber replacing abounding of the adenosine bases. This after-effects in the blockage of DNA synthesis, as phosphodiester bridges can best to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases added finer than it does cellular polymerase, and alternation addendum resumes if ganciclovir is removed.